% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Longuespe:285101,
      author       = {R. Longuespée$^*$ and J. Kunz and M. Fresnais and K. I.
                      Foerster and J. Burhenne and M. Thomas and D. Kazdal and A.
                      Stenzinger and P. Christopoulos and W. E. Haefeli},
      title        = {{T}herapeutic drug monitoring of osimertinib in non-small
                      cell lung cancer and short bowel syndrome: {A} case report.},
      journal      = {British journal of clinical pharmacology},
      volume       = {90},
      number       = {1},
      issn         = {0306-5251},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2023-02225},
      pages        = {344-349},
      year         = {2024},
      note         = {Case report / 2024 Jan;90(1):344-349 / #EA:B350#},
      abstract     = {Short bowel syndrome (SBS) following extensive intestinal
                      resection is often characterized by impaired absorption of
                      orally administered drugs, including tyrosine kinase
                      inhibitors (TKI). We report the case of a patient with
                      EGFR-mutated non-small cell lung carcinoma treated with 80
                      mg/day of the TKI osimertinib who achieved partial response
                      of the tumour, but was subsequently subjected to a
                      double-barrelled jejunostomy due to ileus. Due to the
                      development of SBS after the bypass surgery, plasma
                      concentrations of osimertinib were monitored using mass
                      spectrometry. The therapeutic drug monitoring confirmed a
                      malabsorption of osimertinib in the patient (108 ng/mL,
                      which is below the 5th percentile of the expected plasma
                      concentration) and was useful to guide adjustments of TKI
                      dosing in order to achieve adequate blood levels (161 ng/mL
                      after increase of the dose to 120 mg/day) in order to
                      maintain tumour control.},
      keywords     = {LC-MS/MS (Other) / MALDI-MS/MS (Other) / non-small cell
                      lung cancer (Other) / osimertinib (Other) / short bowel
                      syndrome (Other) / therapeutic drug monitoring (Other)},
      cin          = {B350},
      ddc          = {610},
      cid          = {I:(DE-He78)B350-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37815301},
      doi          = {10.1111/bcp.15924},
      url          = {https://inrepo02.dkfz.de/record/285101},
}